Home > Insider Trading > Filing (0001562180-21-000880)

Filing Details

Accession Number:: 0001562180-21-000880
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-03 20:02:46
Reporting Period:: 2021-02-01

Accepted Time:: 2021-02-03 20:02:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
897448	Amarin Corp Plc	AMRN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1289884	B Steven Ketchum	C/O Amarin Pharma, Inc. 440 Us Highway 22 Bridgewater NJ 08807	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2021-02-01	16,703	$2.50	425,069	No	4	M	Direct
Ordinary Shares	Acquisiton	2021-02-01	164,573	$2.50	589,642	No	4	M	Direct
Ordinary Shares	Acquisiton	2021-02-01	11,082	$2.95	600,724	No	4	M	Direct
Ordinary Shares	Disposition	2021-02-01	192,358	$8.06	408,366	No	4	S	Direct
Ordinary Shares	Disposition	2021-02-01	25,370	$8.03	382,996	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2021-02-01	16,703	$0.00	16,703	$2.50
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2021-02-01	164,573	$0.00	164,573	$2.50
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2021-02-01	11,082	$0.00	11,082	$2.95

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2025-07-06	No	4	M	Direct
2025-07-06	No	4	M	Direct
2027-01-31	No	4	M	Direct

Footnotes

Multiple reportable transactions are reported in the Form 4 including exercises of previously granted stock options and sale of certain shares. The market sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
On July 6, 2015, the Reporting Person was granted an option to purchase 180,000 Ordinary Shares under the Plan. The vesting of the shares was subject to a certain performance milestone that was previously achieved. The shares subject to this option vested in 48 equal monthly installments on the last day of each month starting on July 31, 2015. This option was fully vested as of the date hereof.
On July 6, 2015, the Reporting Person was granted an option to purchase 240,000 Ordinary Shares under the Plan. The vesting of the shares was subject to a certain performance milestone that was previously achieved. The shares subject to this option vested in 48 equal monthly installments on the last day of each month starting on July 31, 2015. This option was fully vested as of the date hereof.
On February 1, 2017, the Reporting Person was granted an option to purchase 133,000 Ordinary Shares under the Plan. The shares subject to this option vested in 48 equal monthly installments on the last day of each month starting on February 28, 2017. This option was fully vested as of the date hereof.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Please see the section titled "Remarks" below for additional information.